Experience at Son Espases University Hospital with daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd) as first line treatment in multiple myeloma

被引：0
|
作者：
Monsonis, Lola Piquer [1 ]
Sampalo, Maria Gali [1 ]
Montana, Albert Perez [1 ]
Raga, Jose Maria Sanchez [1 ]
Mayol, Antonia Sampol [1 ]
机构：
[1] Hosp Univ Son Espases, Palma De Mallorca, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P158
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [1] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
    Sonneveld, Pieter
    Dimopoulos, Meletios A.
    Boccadoro, Mario
    Quach, Hang
    Ho, P. Joy
    Beksac, Meral
    Hulin, Cyrille
    Antonioli, Elisabetta
    Leleu, Xavier
    Mangiacavalli, Silvia
    Perrot, Aurore
    Cavo, Michele
    Belotti, Angelo
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    Nijhof, Inger S.
    van de Donk, Niels W. C. J.
    Katodritou, Eirini
    Schjesvold, Fredrik
    Sureda Balari, Anna
    Rosinol, Laura
    Delforge, Michel
    Roeloffzen, Wilfried
    Silzle, Tobias
    Vangsted, Annette
    Einsele, Hermann
    Spencer, Andrew
    Hajek, Roman
    Jurczyszyn, Artur
    Lonergan, Sarah
    Ahmadi, Tahamtan
    Liu, Yanfang
    Wang, Jianping
    Vieyra, Diego
    van Brummelen, Emilie M. J.
    Vanquickelberghe, Veronique
    Sitthi-Amorn, Anna
    de Boer, Carla J.
    Carson, Robin
    Rodriguez-Otero, Paula
    Blade, Joan
    Moreau, Philippe
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (04): : 301 - 313
  • [2] Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma
    Cook, Joselle
    Johnson, Isla
    Higgins, Alexandra
    Sidana, Surbhi
    Warsame, Rahma
    Gonsalves, Wilson
    Gertz, Morie A.
    Buadi, Francis
    Lacy, Martha
    Kapoor, Prashant
    Dispenzieri, Angela
    Kourelis, Taxiarchis
    Dingli, David
    Fonder, Amie
    Hayman, Suzanne
    Hobbs, Miriam
    Hwa, Yi Lisa
    Kyle, Robert
    Leung, Nelson
    Go, Ronald
    Rajkumar, Vincent S.
    Kumar, Shaji
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (03) : 330 - 337
  • [3] Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma
    Hansen, Doris K.
    Gautam, Santosh
    Lafeuille, Marie-Helene
    Rossi, Carmine
    Moore, Bronwyn
    Tardif-Samson, Anabelle
    Thompson-Leduc, Philippe
    Fu, Alex Z.
    Cortoos, Annelore
    Kaila, Shuchita
    Fonseca, Rafael
    BLOOD, 2023, 142
  • [4] Early mortality and treatment discontinuation in multiple myeloma patients treated in front-line with bortezomib, lenalidomide and dexamethasone (VRD)
    Oriol, Albert
    Canelo-Vilaseca, Marta
    Sanchez, Carla
    Abril, Laura
    Escoda, Lourdes
    Ibarra, Gladys
    Abella, Eugenia
    Motllo, Cristina
    Gonzalez-Montes, Yolanda
    Granada, Isabel
    Cabezudo, Elena
    Senin, Alicia
    Ben, Randa
    Jurado, Rebeca
    de Jaureguizar, Alejandro
    Ribera, Josep-Maria
    Sarra, Josep
    Sancho, Juan-Manuel
    Sureda, Anna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S146 - S147
  • [5] Predictors of response to upfront bortezomib, lenalidomide and dexamethasone (VRd) in multiple myeloma.
    Keruakous, Amany
    Day, Silas
    Borogovac, Azra
    Holter, Jennifer L.
    Asch, Adam Steven
    Yuen, Carrie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Daratumumab, bortezomib, lenalidomide and dexamethasone in multiple myeloma: the advent of modern quadruplets
    Lanier, Louis
    HEMATOLOGIE, 2024, 30 (02): : 106 - 108
  • [7] BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (VRD) AS FIRST-LINE TREATMENT IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA. EXPERIENCE IN NON-CANDIDATE PATIENTS FOR HEMATOPOIETIC PROGENITOR TRANSPLANTATION
    Llorente Dunia, De Miguel
    Lopez Irene, Nuevo
    Munoz Beatriz, Merchan
    Argumanez Marta, Mora
    Perez Angela, Gil
    Ramo Alejandro, Vazquez
    Garcia Helga, Guillen
    Lopez Nuria, Golbano
    Ana Belen, Santos Montero
    Perez Dolores, Subira
    Juanis Jaime, Arbeteta
    HAEMATOLOGICA, 2021, 106 (10) : 340 - 341
  • [8] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Maclachlan, Kylee H.
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander
    Usmani, Saad Z.
    BLOOD, 2023, 142
  • [9] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOLLOWED BY AUTOLOGOUS TRANSPLANTATION AS FIRST LINE TREATMENT IN MULTIPLE MYELOMA. SINGLE CENTER EXPERIENCE
    Arguinano, J. M.
    Zudaire, M.
    Pena, E.
    Aoiz, I.
    Hamdi, M.
    Mateos, M.
    Ardaiz, M.
    Viguria, M.
    Rodriguez Calvillo, M.
    Gorosquieta, A.
    Sanchez Anton, M.
    Quispe, I.
    Arregui, P.
    Montoya, M.
    Garcia Ramirez, P.
    Alvarellos, M.
    HAEMATOLOGICA, 2015, 100 : 735 - 735
  • [10] Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
    M. Hasib Sidiqi
    Mohammed A. Aljama
    Irbaz Bin Riaz
    Angela Dispenzieri
    Eli Muchtar
    Francis K. Buadi
    Rahma Warsame
    Martha Q. Lacy
    David Dingli
    Nelson Leung
    Wilson I. Gonsalves
    Prashant Kapoor
    Taxiarchis V. Kourelis
    William J. Hogan
    S. Vincent Rajkumar
    Shaji K. Kumar
    Morie A. Gertz
    Blood Cancer Journal, 8
12345